StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Stop comparing SZLS to EXAS

<< Previous

Bullboard Posts

Next >>

Comment by gojotv!on Mar 22, 2021 1:45pm

130 Views

Post# 32851194

RE:Stop comparing SZLS to EXAS

True. There is no comparison.
Aristotle is far more comprehensive a test and will initially be available in StageZero labs. You can do tests in-house without FDA approval. They are going to be swamped with demand. Which is great, because it's a better way to manage growth. You can't go from 0 to 10 without going through 2,3,4,5,6,... That's the way to make costly mistakes in business
With that initial success, and a slew of satisfied patients and doctors, the FDA will fast-track Aristotle for commercial use as a breakthrough technology, just like they did with Covid tests.
Good plan.
Cheaper and more effective profit-wise to go that route.
This juggernaut can't be stopped.

Stockish12 wrote: This is how you know most of these guys that just spew prices and projections on here are just plain dumb or wishful gamblers.

Its simple. I do not care if SZLS claims to have a product that can test 10 cancers. The 2 companies are not comparable.

1. Management team: Read up about the Management team of EXAS. It is like day and light when compared with SZLS. Tripp cannot raise 1/10 of what those guys raised in the market. He lacks the technical know how.

2. EXAS's cologuard had its first fda approval in 2014. Aristotle has none and there is nothing in the works towards that. For a product like this to hit the main market, FDA approval is key.

Always do DD and think before posting senseless SPs. At best, this product will hit a few local laboratories. Price may double or triple from here at the most and then fall. Oh wait, thats if the Q1 release is real.